147 related articles for article (PubMed ID: 36803128)
21. BAP1-inactivated melanocytic tumour with borderline histopathological features (BAP1-inactivated melanocytoma): A case report and a reappraisal.
Ferrara G; Mariani MP; Auriemma M
Australas J Dermatol; 2021 Feb; 62(1):e88-e91. PubMed ID: 33107024
[TBL] [Abstract][Full Text] [Related]
22. BAP1-inactivated melanocytic tumors show prominent centrosome amplification and associated loss of primary cilia.
Ye J; Sheahon KM; LeBoit PE; McCalmont TH; Lang UE
J Cutan Pathol; 2021 Nov; 48(11):1353-1360. PubMed ID: 34085298
[TBL] [Abstract][Full Text] [Related]
23. Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Costa S; Byrne M; Pissaloux D; Haddad V; Paindavoine S; Thomas L; Aubin F; Lesimple T; Grange F; Bonniaud B; Mortier L; Mateus C; Dreno B; Balme B; Vergier B; de la Fouchardiere A
Am J Surg Pathol; 2016 Mar; 40(3):368-77. PubMed ID: 26645730
[TBL] [Abstract][Full Text] [Related]
24. Germline mutations in BAP1 predispose to melanocytic tumors.
Wiesner T; Obenauf AC; Murali R; Fried I; Griewank KG; Ulz P; Windpassinger C; Wackernagel W; Loy S; Wolf I; Viale A; Lash AE; Pirun M; Socci ND; Rütten A; Palmedo G; Abramson D; Offit K; Ott A; Becker JC; Cerroni L; Kutzner H; Bastian BC; Speicher MR
Nat Genet; 2011 Aug; 43(10):1018-21. PubMed ID: 21874003
[TBL] [Abstract][Full Text] [Related]
25. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.
Njauw CN; Kim I; Piris A; Gabree M; Taylor M; Lane AM; DeAngelis MM; Gragoudas E; Duncan LM; Tsao H
PLoS One; 2012; 7(4):e35295. PubMed ID: 22545102
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.
Walpole S; Pritchard AL; Cebulla CM; Pilarski R; Stautberg M; Davidorf FH; de la Fouchardière A; Cabaret O; Golmard L; Stoppa-Lyonnet D; Garfield E; Njauw CN; Cheung M; Turunen JA; Repo P; Järvinen RS; van Doorn R; Jager MJ; Luyten GPM; Marinkovic M; Chau C; Potrony M; Höiom V; Helgadottir H; Pastorino L; Bruno W; Andreotti V; Dalmasso B; Ciccarese G; Queirolo P; Mastracci L; Wadt K; Kiilgaard JF; Speicher MR; van Poppelen N; Kilic E; Al-Jamal RT; Dianzani I; Betti M; Bergmann C; Santagata S; Dahiya S; Taibjee S; Burke J; Poplawski N; O'Shea SJ; Newton-Bishop J; Adlard J; Adams DJ; Lane AM; Kim I; Klebe S; Racher H; Harbour JW; Nickerson ML; Murali R; Palmer JM; Howlie M; Symmons J; Hamilton H; Warrier S; Glasson W; Johansson P; Robles-Espinoza CD; Ossio R; de Klein A; Puig S; Ghiorzo P; Nielsen M; Kivelä TT; Tsao H; Testa JR; Gerami P; Stern MH; Paillerets BB; Abdel-Rahman MH; Hayward NK
J Natl Cancer Inst; 2018 Dec; 110(12):1328-1341. PubMed ID: 30517737
[TBL] [Abstract][Full Text] [Related]
27. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
[TBL] [Abstract][Full Text] [Related]
28. Gene of the month: BAP1.
Wang A; Papneja A; Hyrcza M; Al-Habeeb A; Ghazarian D
J Clin Pathol; 2016 Sep; 69(9):750-3. PubMed ID: 27235536
[TBL] [Abstract][Full Text] [Related]
29. Melanoma arising in plaque-type blue nevus and dermal melanocytosis: Diagnostic and prognostic value of BAP1.
Requena C; Traves V; Ferrandis E; Antón Almero M; García-Casado Z; Manrique-Silva E; Santos Briz Á; Escalonilla P; Nagore E
Actas Dermosifiliogr; 2023; 114(7):636-641. PubMed ID: 37088284
[TBL] [Abstract][Full Text] [Related]
30. RAF1 Gene Fusions as a Possible Driver Mechanism in Rare BAP1-Inactivated Melanocytic Tumors: A Report of 2 Cases.
Donati M; Martinek P; Kastnerova L; Persichetti P; Michal M; Kazakov DV
Am J Dermatopathol; 2020 Dec; 42(12):961-966. PubMed ID: 32769548
[TBL] [Abstract][Full Text] [Related]
31. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.
Wiesner T; Murali R; Fried I; Cerroni L; Busam K; Kutzner H; Bastian BC
Am J Surg Pathol; 2012 Jun; 36(6):818-30. PubMed ID: 22367297
[TBL] [Abstract][Full Text] [Related]
32. Melanoma Ex Blue Nevus With GNA11 Mutation and BAP1 Loss: Case Report and Review of the Literature.
Chang LW; Kazlouskaya V; Kazi R; Davar D; Ferris RL; Ho J; Karunamurthy A; Jedrych JJ; Bunimovich YL
Am J Dermatopathol; 2020 Nov; 42(11):854-857. PubMed ID: 32310862
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Zauderer MG; Jayakumaran G; DuBoff M; Zhang L; Francis JH; Abramson DH; Cercek A; Nash GM; Shoushtari A; Chapman P; D'Angelo S; Arnold AG; Siegel B; Fleischut MH; Ni A; Rimner A; Rusch VW; Adusumilli PS; Travis W; Sauter JL; Zehir A; Mandelker D; Ladanyi M; Robson M
J Thorac Oncol; 2019 Nov; 14(11):1989-1994. PubMed ID: 31323388
[TBL] [Abstract][Full Text] [Related]
34. A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors.
Redon S; Guibourg B; Talagas M; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2018; 26(10):714-720. PubMed ID: 28362709
[TBL] [Abstract][Full Text] [Related]
35. Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.
Aung PP; Nagarajan P; Tetzlaff MT; Curry JL; Tang G; Abdullaev Z; Pack SD; Ivan D; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2019 Mar; 41(3):167-179. PubMed ID: 30801340
[TBL] [Abstract][Full Text] [Related]
36. BAP1-deficient and VE1-negative atypical Spitz tumor.
Requena C; Sanz V; Nagore E; García-Casado Z; Rubio L; Guillén C; Kutzner H
J Cutan Pathol; 2015 Aug; 42(8):564-7. PubMed ID: 25953246
[TBL] [Abstract][Full Text] [Related]
37. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.
Pilarski R; Cebulla CM; Massengill JB; Rai K; Rich T; Strong L; McGillivray B; Asrat MJ; Davidorf FH; Abdel-Rahman MH
Genes Chromosomes Cancer; 2014 Feb; 53(2):177-82. PubMed ID: 24243779
[TBL] [Abstract][Full Text] [Related]
38. A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.
McDonnell KJ; Gallanis GT; Heller KA; Melas M; Idos GE; Culver JO; Martin SE; Peng DH; Gruber SB
Cancer Genet; 2016 Mar; 209(3):75-81. PubMed ID: 26774355
[TBL] [Abstract][Full Text] [Related]
39. BAP1 deficient malignant melanoma arising from the intradermal component of a congenital melanocytic naevus.
Ardakani NM; Palmer DL; Wood BA
Pathology; 2015 Dec; 47(7):707-10. PubMed ID: 26517632
[No Abstract] [Full Text] [Related]
40. BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!
Duncan LM; Tetzlaff MT
J Cutan Pathol; 2020 May; 47(5):459-461. PubMed ID: 32096236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
